Novavax COVID-19 Vaccine and Booster

Nov. 8, 2022

The Food and Drug Administration has approved the use of a fourth COVID-19 vaccine and booster from Novavax! The Novavax vaccine is 90% effective against symptomatic COVID-19 infections, and provides 100% protection against moderate and severe disease. Using a traditional protein-based vaccine that uses only part of the virus that is delivered directly to the cells, Novavax differs from the mRNA approach taken by Pfizer-BioNTech, Moderna, and Johnson and Johnson. All Individuals ages 12 and older are eligible for the two shot primary series, and can get the second shot three to eight weeks after their initial vaccine. 

In October 2022, the FDA approved the Novavax booster for individuals ages 18 and older, although it may not be as effective in protecting against newer variants of COVID-19. The protein-based vaccine allows individuals who weren’t able to get the other vaccines due to health conditions the opportunity to get vaccinated. Provide your constituents with options to get the Novavax vaccine, or other COVID-19 and flu vaccines near them through the vaccine finder!